Press release
Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018
the global ophthalmic drug market is projected to reach £30 billion by 2023, growing at a CAGR of 5.3% from 2017 to 2023.
Ophthalmic News:
Elasmogen: Dr Caroline Barelle named “Rising Stars: Extraordinary Talent"
The CEO of Elasmogen, Dr Caroline Barelle was named as the winner in the "Rising Stars: Extraordinary Talent (2017)" category at Scotland's Life Sciences Dinner & Annual Awards, held at the Hilton hotel Glasgow and attended by over 700 of Scotland's top Life Sciences industry leaders on 16 May 2018.
Dr Barelle founded Elasmogen Ltd in 2016 and has rapidly established the company as a global biotech with an international profile and late-stage, pre-clinical products positioned to make a “sight-saving” difference in ophthalmology. This award also recognises Dr Barelle’s success at securing collaborative partnerships with companies that include Almac Discovery Ltd and the US bio-pharmaceutical giant, Amgen Inc.
Join Caroline this November, as she presents: 'soloMERs™ - Site-specific Biologics for Ocular Disease.'
Details below:
- Advantages of soloMERs
- Isolation and characterisation of target specific soloMERs
- Efficacy in pre-clinical models of disease
- Elasmogen’s ocular portfolio
Spark Therapeutics: A Constellation of Inherited Retinal Diseases (IRDs)
Inherited retinal diseases (also called inherited retinal dystrophies, or IRDs) are a group of rare eye disorders caused by an inherited gene mutation and can result in vision loss or blindness. The conditions vary, but those with IRDs may face many similar challenges, including night blindness (nyctalopia), declining vision, or blindness at birth.
Explore the future of ocular gene editing in inherited retinal diseases as Dr. Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics presents: 'New horizon for treatment of inherited retinal dystrophy.'
Details below:
- Voretigene: The first gene therapy approved in ophthalmology
- Other up-coming gene therapy trials in the pipeline
- Market access difficulties for gene therapy
Alimera Sciences: Retinal Diseases - Moving the back of the eye to the forefront of research and development
At Alimera Sciences retinal disease is kept at the forefront. Their commitment to retina specialists and their patients is manifest in the product and development portfolio which is designed to treat early- and late-stage diseases such as diabetic macular edema.
Philip Ashman, Senior Vice President, Managing Director Europe, Alimera Sciences will examine: 'The challenge of replicating clinical trial performance of intravitreal therapies in the ophthalmology clinic.'
Details below:
- Review the development of practice in treatment of diabetic macular oedema
- The challenges of accepting innovation into everyday practice
- The emergence of “Real-World” data collection and lessons learned
- A look into the future
Download a copy of the agenda online for full details on all presentations
Event Info:
Some other notable areas of interest are current unmet needs for geographic atrophy, genetically defined therapies in AMD, preservative free and connected devices and other novel drug delivery strategies.
The event will address the impact of the overwhelming digitalisation such as artificial intelligence in drug discovery and how companies, from biotech's to pharma, need to adapt. It will also explore new strategies for treating retinal vascular diseases, the future of ocular gene editing and a regulatory perspective of the industry.
Hear from opinion leaders such as Roche, Santen, Aerie Pharmaceuticals, MHRA, Nightstar Therapeutics, Santen + more.
For those looking to attend, there is currently a £300 early-bird saving, ending June 29th.
Download the 2018 agenda online and see the full speaker line-up and presentations, as well as the attendee list from last year at: www.ophthalmicdrugs.com/opr
SMi presents the 2nd annual:
Ophthalmic Drugs 2018
Date: 26th – 27th November 2018
Workshops: 28th November 2018
Location: Copthorne Tara Hotel, London UK
Website: www.ophthalmicdrugs.com/opr
Sponsors: Experimentica | Nemera
Follow 'SMi Pharma' on LinkedIn for latest pharmaceutical industry updates.
Sources: Allied Market Research | Elasmogen | aSharedVision | Alimera Sciences
---end---
Contact Information:
For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
1
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Your Latest Ophthalmology News for SMi’s Ophthalmic Drugs 2018 here
News-ID: 1098167 • Views: …
More Releases from SMi Group
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Ophthalmic
Ophthalmic Trial Frames Market Depth Survey Report 2019| Topcon, Luneau, Takagi …
Ophthalmic trial frames are adjustable frames that are used to hold lenses during refraction test and during retinoscopy test of the eye. Ophthalmic trial frames are eyeglasses designed in such a way that different lenses can be inserted and can be used to correct refractive errors of vision. Ophthalmic trial frames are light weight, adjustable and should have a comfortable nose resting and can be adjusted to allow accurate centering.…
Ophthalmic Eye Shield Market Segmentation By Material type Aluminium Ophthalmic …
Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization,…
Eye socket Implants Market Offered in New Research Forecasted through 2026 // Ke …
The global Eye socket Implants market is expected to see remarkable growth in the forecast period due to increase in work-related eye injuries. Increase in the number of patients drives the overall eye socket implants market. Higher adoption of surgeries in higher economic regions propels the Eye socket Implants Market. Others factors like increasing prevalence and incidence of eye-related disease, changing lifestyle pattern are the factors which are fueling the…
Ophthalmic Surgical Technologies Market - Femtosecond Systems Likely to Dominate …
The global ophthalmic surgical technologies market is driven mainly by the growing funding in the healthcare sector and the rising awareness about eye care, added to the rising prevalence of eye diseases. The ophthalmic surgical technologies market has enjoyed a supportive regulatory and economic structure in most regions in the recent past and is thus likely to continue on the strong growth trajectory it has exhibited in recent years. Increasing…
Ophthalmic Lasers Market: Demand for Ophthalmic Lasers to Remain Higher in North …
Lasers have become an essential part of treatment modality for a number of practicing ophthalmologist. Ophthalmic lasers have gained prominence with the popularity of laser-assisted surgeries for rectifying nearsightedness or myopia. The increasing incidence of ophthalmic disorders and rise in geriatric population in various regions have boosted the application of different types of lasers in treating specific eye problems and improving vision. Technological advances have significantly increased the safety and…
Ophthalmic Ultrasound Device Market: A-scan Ophthalmic Ultrasound Devices High i …
Global Ophthalmic Ultrasound Device Market: Snapshot
The constantly increasing percentage of the geriatric population across the world is widely considered as the primary factor augmenting the demand for ophthalmic ultrasound devices. The high geriatric population is directly linked to the increasing patient count for ocular diseases and disorders, along with chronic diseases such as diabetes. The increasing levels of pollution are also responsible for the high volume of ovular disorders across…
